Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.18B | 2.07B | 2.09B | 1.90B | 1.65B | 1.34B |
Gross Profit | 1.13B | 1.09B | 1.21B | 1.13B | 967.21M | 745.52M |
EBITDA | 389.80M | 403.06M | 502.77M | 482.36M | 409.21M | 266.41M |
Net Income | 150.13M | 178.73M | 290.40M | 293.91M | 236.28M | 122.39M |
Balance Sheet | ||||||
Total Assets | 0.00 | 3.39B | 3.03B | 2.82B | 2.40B | 2.01B |
Cash, Cash Equivalents and Short-Term Investments | 26.55M | 20.29M | 10.60M | 7.73M | 7.44M | 5.20M |
Total Debt | 0.00 | 151.35M | 155.70M | 127.90M | 121.27M | 68.61M |
Total Liabilities | -2.09B | 1.34B | 860.02M | 792.73M | 718.59M | 562.73M |
Stockholders Equity | 2.09B | 2.04B | 2.16B | 2.02B | 1.66B | 1.43B |
Cash Flow | ||||||
Free Cash Flow | 109.01M | 95.11M | 137.00M | 106.23M | 296.56M | 133.54M |
Operating Cash Flow | 169.31M | 247.32M | 250.86M | 188.20M | 362.66M | 178.53M |
Investing Cash Flow | -460.40M | -412.31M | -110.98M | -148.89M | -75.20M | -71.95M |
Financing Cash Flow | 309.56M | 176.25M | -135.09M | -38.24M | -285.89M | -122.96M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | €13.54B | 20.74 | 4.83% | 3.05% | 0.53% | 23.79% | |
69 Neutral | €14.28B | 98.10 | 5.01% | 0.38% | 5.82% | 59.90% | |
67 Neutral | €4.08B | 25.78 | 7.48% | 1.27% | 5.21% | -39.36% | |
66 Neutral | €1.06B | 28.87 | 17.61% | 0.96% | 9.42% | 9.54% | |
64 Neutral | €1.27B | 14.49 | 6.87% | 2.64% | -0.03% | -14.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €1.31B | 64.15 | ― | 0.10% | -18.82% | -113.85% |
Study Overview: Carl Zeiss Meditec is conducting a clinical study titled ‘EPIC: Evaluation of the Postoperative Cataract Surgery Outcomes in Patients With Prior Corneal Laser Vision Correction Implanted With the CT LUCIA Intraocular Lens.’ The study aims to assess the visual and refractive outcomes in patients who have undergone myopic corneal laser vision correction and are now receiving the CT LUCIA 621P intraocular lens during cataract surgery. This research is significant as it seeks to improve understanding of postoperative results in this specific patient group.